BMS Group expands in Turkey with Oria purchase
Financial terms of the deal remain undisclosed.
The move is part of BMS Group's plan to extend its reach into the Middle East and enhance its capabilities in providing client-focused solutions.
Established in 2019, Oria offers corporate insurance and employee health benefits solutions.
The acquisition is expected to bring more 'competitive' and 'holistic' services to both local and international clients, and insurance partners.
BMS Turkey CEO Kerim Gürkan said: "This is an integration of two like-minded businesses. Over the past three years, BMS has established itself in Turkey as a leading specialty broker with strong international capacity. Now, by joining forces with Oria's experienced team and local insight, we enter an exciting new chapter – broadening our client base and deepening the value we bring to both clients and insurance partners, locally and globally."
Oria owner and chairman Cenk Erden, along with executive vice-president Remzi Duman, will join the Board of BMS Turkey.
The combined operations will operate under the name BMS Group Sigorta ve Reasurans Brokerligi.
Erden added: "This partnership brings together Oria's local market knowledge with BMS's international strength and vision. It is a natural fit built on shared values and a commitment to delivering high-impact, high-value solutions. We are thrilled to join BMS and contribute to its ambitious growth journey."
This continues BMS Group's acquisition spree, which includes David Roberts & Partners in the UK and Rasher in Spain.
Additionally, BMS Group is planning to foray into the Dubai International Financial Centre, pending regulatory approval.
Last month, BMS Group appointed Jean-Jacques Henchoz as Board chairman, effective 1 May.
"BMS Group expands in Turkey with Oria purchase " was originally created and published by Life Insurance International, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
3 hours ago
- Forbes
Israeli Startups Using AI To Accelerate Drug Discovery
AI Aiding in drug discovery Israel-based AION Labs wants to drive AI to revolutionize pharmaceutical drug discovery and development. AION is an innovative venture that brings together pharmaceutical heavyweights—Pfizer, AstraZeneca, Teva, and Merck—with entrepreneurial scientists, technology leaders, and successful investors. 'We are a venture studio that builds startups using computational technologies and artificial intelligence to unleash new capabilities to discover and develop new drugs with a venture model that we invented,' says Mati Gill, CEO of AION. This unique collaboration addresses a costly endeavor that is crucial to the quality of our lives. It takes $5 billion and ten years to bring a new drug to market. The world's top 20 pharmaceutical companies collectively spent $145 billion on R&D in 2022-23, according to a recent Deloitte report, which also noted 'AI is yet to become a 'game-changer' in pharma R&D.' A more comprehensive survey of 4,191 pharmaceutical companies worldwide, published in Nature Reviews Drug Discovery, found that they spent $276 billion on R&D in 2021. These R&D expenses have increased tenfold since the 1980s (after adjusting for inflation), and pharmaceutical companies now allocate approximately 25% of their revenue to R&D, nearly double the share seen in the early 2000s, according to CB Insights. 'AI could potentially cut years off the discovery process and compress clinical trial times by up to 30%. This would accelerate the delivery of new treatments to patients, unlock novel treatment approaches, and enable more personalized medicine,' noted CBI. Another CBI report, on the AI readiness of pharmaceutical companies, highlighted the importance of external collaboration, 'as breakthrough innovations increasingly emerge from partnerships rather than internal development alone.' Gill predicts that by 2030, the first truly AI-designed drugs will reach regulatory approval. He believes that Israel is uniquely positioned to be a leading ecosystem in transforming the global biotech and pharmaceutical landscape, given its strengths in multidisciplinary scientific discovery, entrepreneurial innovation, computational biology and big data analysis, as well as a robust and integrated healthcare system, and strong government support. 'For the first time, Israel's strengths are coinciding with what the future of the industry is going to be,' says Gill. There are three core principles behind every startup that AION selects and supports, explains Gill: they address a validated, well-defined, industry-wide problem statement; there's a multidisciplinary team that has expertise in both AI and biology and a technology that can solve that problem statement; and that at least one of AION' pharmaceutical partners is willing to commit to working with the startup to initially develop their technology and conduct with them a proof-of-concept at an early stage. The R&D teams of AION Labs' partners help select the specific industry-wide challenges to focus on and the technologies and scientist-led startups that will develop the solutions. To accomplish that, AION has established two tracks, one starting with the problem statement and the other starting with the technology. DenovAI is an example of starting with the problem statement. Is it possible to design proteins 'de novo' or completely from scratch? 'We ran a challenge and had 15 great candidates,' recounts Gill. 'We selected a senior scientist who had developed a technology called AlphaDesign that is basically doing the inverse of the famous AlphaFold.' The startup recently demonstrated its ability to generate new proteins with measurable, targeted function. Its AI-based platform for rapid de novo antibody discovery could reduce the discovery process from months to days, and broaden the scope of therapy to a wide range of diseases. Cassidy Bio is an example of starting with the technology. It is using large language models or LLMs to design new guide RNAs, unlocking the capability of gene therapy in a scalable and precise manner. Guide RNAs or gRNAs serve as the 'GPS' for CRISPR systems, directing the editing machinery to precise genetic targets. The design of gRNAs plays a critical role in determining both the efficacy and safety of gene-editing therapeutics. Professor Ayal Hendel of Israel's Bar-Ilan University, a leading expert in genome editing and gene therapy, teamed up with two experienced entrepreneurs to establish the startup. With AION Labs' help, they raised $8 million in seed funding and are working with AstraZeneca to validate their technology. Based on proprietary, clinically relevant genomic data generation, state-of-the-art predictive algorithms, and rigorous wet lab validation, Cassidy Bio is developing the first comprehensive predictive platform based on LLMs for gRNA design. Unlike the data driving AI consumer applications, which is mostly based on internet-scraped data, pharmaceutical data is proprietary data. AION Labs' unique collaborative model provides access to pharmaceutical firms' R&D teams and their data, along with a secure sharing environment facilitated by AION's tech partner, Amazon's cloud service. This means the pharmaceutical companies can share their proprietary data with the startups in AION Labs' portfolio, but not with each other. AION Labs is also a member of Israel's 8400 The Health Network. This network was founded in 2017 on the premise that HealthTech is Israel's next economic growth engine and that Israel has what it takes to become a game-changing player in the global HealthTech revolution, according to its CEO, Ari Strasberg. To date, the non-profit organization has developed numerous programs and national initiatives, ranging from HealthIL, which bridges the gap between healthcare systems and technology by facilitating over 1,300 pilots and implementing 160 projects, to Helix, which strengthens the working relationships between 46 top U.S. and Israeli HealthTech leaders. The organization has been very successful, says Strasberg, in creating a public-private partnership, connecting government programs with 'the needs of the ecosystem.' Another success story is the development of FIRE, the data interoperability standard used by the healthcare systems in Israel. Going forward, Strasberg would like 8400 to play a major role in increasing the number of very successful Israeli HealthTech startups. 'We have a few, but not enough,' says Strasberg. 'We need to have a few blockbuster ones that carry the entire ecosystem with them.'
Yahoo
6 hours ago
- Yahoo
Man Utd outcast Antony 'open' to joining Cristiano Ronaldo in Saudi Pro League as 'several clubs' ask transfer questions of Brazilian winger
Brazilian enjoyed productive loan at Betis Red Devils willing to listen to offers Could embrace riches in the Middle East Follow GOAL on WhatsApp! 🟢📱 WHAT HAPPENED? The Brazil international has not travelled to the United States as part of Ruben Amorim's plans for a pre-season tour. He is expected to seal another move away from Old Trafford in the summer transfer window. THE BIGGER PICTURE United allowed Antony to link up with Real Betis in January, with a productive loan spell in Spain delivering nine goals and five assists. His exploits there have attracted admiring glances from around the world. DID YOU KNOW? Betis were keen to get another deal done, but lack the funds required to agree a permanent transfer. United need to make at least £32.58 million ($44m) on a player that they signed for £85m ($114m) in order to avoid making a loss under Profit and Sustainability Rules (PSR). WHAT ANTONY'S AGENT SAID Teams in the Middle East would have no problem meeting that asking price, with Antony's representative Junior Pedroso telling WinWin: "What I can say is that the player is on the market, and there are several clubs that want to know his current status. We listen to the projects and analyse them. But he is open to moving to Saudi Arabia. Anything is possible, we are looking for what is best for him." WHAT NEXT? Antony is under contract with United until 2027, with the option for a 12-month extension beyond that point. He is one of several players that Amorim is looking to move on, with fellow winger Marcus Rashford having already left for Barcelona.
Yahoo
6 hours ago
- Yahoo
Cincinnati Financial (CINF) Reports Earnings Tomorrow: What To Expect
Property casualty insurer Cincinnati Financial (NASDAQ:CINF) will be announcing earnings results this Monday after the bell. Here's what investors should know. Cincinnati Financial missed analysts' revenue expectations by 5.8% last quarter, reporting revenues of $2.57 billion, up 10.5% year on year. It was a slower quarter for the company, with a miss of analysts' net premiums earned estimates and a miss of analysts' book value per share estimates. Is Cincinnati Financial a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Cincinnati Financial's revenue to grow 13.2% year on year to $2.88 billion, a reversal from the 2.3% decrease it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.39 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Cincinnati Financial has missed Wall Street's revenue estimates six times over the last two years. Looking at Cincinnati Financial's peers in the property & casualty insurance segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Stewart Information Services delivered year-on-year revenue growth of 20.1%, beating analysts' expectations by 9.2%, and First American Financial reported revenues up 14.2%, topping estimates by 4.9%. Stewart Information Services traded up 10.3% following the results while First American Financial was also up 3.5%. Read our full analysis of Stewart Information Services's results here and First American Financial's results here. Debates over possible tariffs and corporate tax adjustments have raised questions about economic stability in 2025. While some of the property & casualty insurance stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 2.9% on average over the last month. Cincinnati Financial is up 1.7% during the same time and is heading into earnings with an average analyst price target of $158.33 (compared to the current share price of $148.75). Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Sign in to access your portfolio
